Which drugs go off patent in 2026?
Two blockbuster drugs with $11.1B in 2025 worldwide sales lose US exclusivity in 2026, led by Farxiga (AstraZeneca, $8.4B). Both are small-molecule drugs that go generic.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Farxiga | AstraZeneca | Cardiometabolic | $8.4B | Generics launched | Copies on the US market | 2026 · −68% |
| Pomalyst | Bristol Myers Squibb | Oncology | $2.7B | Generics launched | Copies on the US market | 2027 · −60% |
Every date here is fixed by a launch, settlement, court ruling or company guidance. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| AstraZeneca | Farxiga | $8.4B | 14% |
| Bristol Myers Squibb | Pomalyst | $2.7B | 5.7% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Generic launches usually take most of a drug's US volume within months. Farxiga and Pomalyst were also selected for Medicare price negotiation, which can cut Medicare revenue before or alongside US copies.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →